Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19 LEARN MORE PFIZER INVESTS $120MIL IN BIOTECH INNOVATION LEARN MORE Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027 LEARN MORE AGREEMENT REACHED WITH COVAX FOR ADVANCE PURCHASE OF COVID-19 VACCINE LEARN MORE RECENT PRESS RELEASES 11/11/2020 - Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2 06/11/2020 - Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS) 05/11/2020 - Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock 30/10/2020 - Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn 27/10/2020 - FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis 27/10/2020 - PFIZER REPORTS THIRD-QUARTER 2020 RESULTS 21/10/2020 - Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020 09/10/2020 - PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint 08/10/2020 - Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency 07/10/2020 - Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment 06/10/2020 - BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2 01/10/2020 - Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy 28/09/2020 - U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis 24/09/2020 - Pfizer Declares Fourth-Quarter 2020 Dividend 23/09/2020 - FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 Next page Next › Last page Last »